Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the pulmonary and metastases lesions objective
response rate after Icotinib preoperative therapy in EGFR-mutant stage IIIB or
oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by
surgery.